ATI-2231 / Aclaris - LARVOL DELTA

ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Washington University School of Medicine | N=36 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor

ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=36 | Suspended | Sponsor: Washington University School of Medicine | Not yet recruiting ➔ Suspended

Metastases • Trial suspension • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire) - "Aclaris is supporting Washington University in a first-in-human investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies. Aclaris expects clinical development activities to be initiated in the second half of 2023."

Trial status • Oncology • Solid Tumor

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire) - "ATI-2231, an investigational oral MK2 inhibitor compound: Currently being explored as a potential treatment for pancreatic cancer and metastatic breast cancer as well as in preventing bone loss in patients with metastatic breast cancer...Aclaris expects clinical development activities to be initiated in 2023, which is expected to advance as a collaboration with an academic third party."

New trial • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Washington University School of Medicine | Phase classification: P1/2 ➔ P1 | N=174 ➔ 36 | Trial completion date: Oct 2030 ➔ Feb 2025 | Trial primary completion date: Oct 2030 ➔ Feb 2025

Enrollment change • Metastases • Phase classification • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - P1/2 | N=174 | Not yet recruiting | Sponsor: Washington University School of Medicine

Combination therapy • Metastases • New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • IL10 • IL6

Aclaris Therapeutics Provides 2023 Outlook (GlobeNewswire) - "ATI-2231, an investigational oral MK2 inhibitor compound: Currently being explored as a potential treatment for pancreatic cancer and metastatic breast cancer as well as in preventing bone loss in patients with metastatic breast cancer...Aclaris expects an IND to be submitted in 2023."

IND • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) - "Aclaris Therapeutics, Inc...announced its financial results for the second quarter of 2022 and provided a corporate update....ATI-2231, an investigational oral MK2 inhibitor compound: Currently being explored as a potential treatment for pancreatic cancer and metastatic breast cancer as well as in preventing bone loss in patients with metastatic breast cancer...IND-enabling studies are underway, and Aclaris expects to submit an IND by the end of 2022."

IND • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer